The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system
Open accessAbstract
Chromosomal rearrangements have a central role in the pathogenesis of human cancers and often result in the expression of therapeutically actionable gene fusions. A recently discovered example is a fusion between the genes echinoderm microtubule-associated protein like 4 (EML4) and anaplastic lymphoma kinase (ALK), generated by an inversion on the short arm of chromosome 2: inv(2)(p21p23). The EML4-ALK oncogene is detected in a subset of human non-small cell lung cancers (NSCLC) and is clinically relevant because it confers sensitivity to ALK inhibitors. Despite their importance, modelling such genetic events in mice has proven challenging and requires complex manipulation of the germ line. Here we describe an efficient method to induce specific chromosomal rearrangements in vivo using viral-mediated delivery of the CRISPR/Cas9 system to somatic cells of adult animals. We apply it to generate a mouse model of Eml4-Alk-driven lung cancer. The resulting tumours invariably harbour the Eml4-Alk inversion, express the Eml4-Alk fusion gene, display histopathological and molecular features typical of ALK(+) human NSCLCs, and respond to treatment with ALK inhibitors. The general strategy described here substantially expands our ability to model human cancers in mice and potentially in other organisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although these events occur at low frequency, they could be significant in a clinical setting if rare translocations led to cancer 97-99 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [98]
Experimental — accuracy not yet measuredIn the citing paper
“In addition, CRISPR/Cas9 system has shown potentials in polygenetic diseases, such as cancer, by inhibiting oncogene expression or deactivating oncogenic virus [52–55].”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [55]
In the citing paper
“To establish disease models, in 2014, Maddalo et al. generated a model of non-small cell lung cancer by creating an Eml4 and Alk fusion gene through the intratracheal instillation of AdV-delivered CRISPR/Cas9 [35].”
From Viral Delivery Systems for CRISPR (2019) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,477
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953
CRISPR/Cas, the Immune System of Bacteria and Archaea
Horvath, P., & Barrangou, R. (2010) · Science · doi:10.1126/science.1179555 · Cited by 2,471
Fusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's Lymphoma
Morris, S. W., Kirstein, M. N., Valentine, M. B., Dittmer, K., Shapiro, D. N., Saltman, D. L., & Look, A. T. (1994) · Science · doi:10.1126/science.8122112 · Cited by 2,428
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-rasPreprint
Jackson, E. L., Willis, N. A., Mercer, K. L., Bronson, R. T., Crowley, D. G., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,927
The anaplastic lymphoma kinase in the pathogenesis of cancer
Chiarle, R., Voena, C., Ambrogio, C., Piva, R., & Inghirami, G. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2291 · Cited by 896
Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase
DuPage, M. J. P., Dooley, A. L., & Jacks, T. (2009) · Nature Protocols · doi:10.1038/nprot.2009.95 · Cited by 873
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 633
Annunziato, S., Barazas, M., Rottenberg, S., & Jonkers, J. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.030924 · Cited by 12
Merle, N., Elmshäuser, S., Straßheimer, F., Wanzel, M., König, A. M., Funk, J. S., Neumann, M., Kochhan, K., Helmprobst, F., Pagenstecher, A., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01661-2 · Cited by 11
Chromosome fusions triggered by noncoding RNA
Bracht, J. R., Wang, X., Shetty, K. S., Chen, X., Uttarotai, G. J., Callihan, E. C., McCloud, S., Clay, D. M., Wang, J., Nowacki, M., et al. (2016) · RNA Biology · doi:10.1080/15476286.2016.1195940 · Cited by 11
Engineering chromosome rearrangements in cancer
Alonso, S., & Dow, L. E. (2021) · Disease Models & Mechanisms · doi:10.1242/dmm.049078 · Cited by 11
Upregulation of complement proteins in lung cancer cells mediates tumor progression
Kleczko, E. K., Poczobutt, J. M., Navarro, A., Laskowski, J., Johnson, A. M., Korpela, S. P., Gurule, N. J., Heasley, L. E., Hopp, K., Weiser-Evans, M. C. M., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1045690 · Cited by 11
Applications and advancements of CRISPR-Cas in the treatment of lung cancer
Pan, L., Ju, Y., Peng, F., & Luo, J. D. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1295084 · Cited by 11
CRISPR/Cas9: a breakthrough in generating mouse models for endocrinologists
Markossian, S., & Flamant, F. (2016) · Journal of Molecular Endocrinology · doi:10.1530/jme-15-0305 · Cited by 11
Concepts and tools for gene editing
Josa, S., Seruggia, D., Fernández, A., & Montoliu, L. (2016) · Reproduction Fertility and Development · doi:10.1071/rd16396 · Cited by 11
Applications of CRISPR-Cas9 Technology in Translational Research on Solid-Tumor Cancers
Chen, P. A., You, L., & Lü, Y. (2018) · The CRISPR Journal · doi:10.1089/crispr.2017.0001 · Cited by 12
Applications and advances of CRISPR/Cas9 in animal cancer model
Xu, M., Weng, Q., & Ji, J. (2020) · Briefings in Functional Genomics · doi:10.1093/bfgp/elaa002 · Cited by 11
The application of somatic CRISPR‐Cas9 to conditional genome editing in Caenorhabditis elegans
Li, W., & Ou, G. (2016) · genesis · doi:10.1002/dvg.22932 · Cited by 11
Huang, P., Wei, G., Kirkpatrick, J. D., Lin, Y., Tan, L., Matta, H., Nasser, I. A., Huang, M., Chen, L., Petitjean, M. M., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.07.016 · Cited by 10
Advancements in Gene Therapy for Non-Small Cell Lung Cancer: Current Approaches and Future Prospects
Ziółkowska‐Suchanek, I., & Rozwadowska, N. (2025) · Genes · doi:10.3390/genes16050569 · Cited by 10
Stepwise molecular specification of excitatory synapse diversity onto cerebellar Purkinje cells
Paul, M. A., Sigoillot, S. M., Marti, L., Quiroz, F. J. U., Delagrange, M., Cheung, H. W., Martinelli, D. C., Oriol, E., Hakim, V., Mailly, P., et al. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01826-w · Cited by 13
CRISPR-Cas9 Therapies in Experimental Mouse Models of Cancer
Estêvão, D., Costa, N. R., da Costa, R. M. G., & Medeiros, R. (2018) · Future Oncology · doi:10.2217/fon-2018-0028 · Cited by 10
Platforms of in vivo genome editing with inducible Cas9 for advanced cancer modeling
Jo, N., Sogabe, Y., Yamada, Y., Ukai, T., Kagawa, H., Mitsunaga, K., Woltjen, K., & Yamada, Y. (2018) · Cancer Science · doi:10.1111/cas.13924 · Cited by 10
Genome editing: An essential technology for cancer treatment
Tufail, M. (2022) · Medicine in Omics · doi:10.1016/j.meomic.2022.100015 · Cited by 10
Obrecht, M., Zurbruegg, S., Accart, N., Lambert, C., Doelemeyer, A., Ledermann, B., & Beckmann, N. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1177421 · Cited by 9
Applications of CRISPR technology to lung cancer research
Sorolla, A., Parisi, E., Sorolla, M. A., Marqués, M., & Porcel, J. M. (2021) · European Respiratory Journal · doi:10.1183/13993003.02610-2021 · Cited by 9
Lv, W., Wang, H., Peng, J., Wang, Y., Jiang, J., & Li, C. (2017) · Oncotarget · doi:10.18632/oncotarget.21136 · Cited by 9
Mishra, A. K., Emamgholi, F., Erlangga, Z., Hartleben, B., Unger, K., Wolff, K., Teichmann, U., Kessel, M., Woller, N., Kühnel, F., et al. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz108 · Cited by 9
Self-citationApplications of genome editing on laboratory animals
Galichet, C., & Lovell-Badge, R. H. (2021) · Laboratory Animals · doi:10.1177/0023677221993141 · Cited by 9
piRNA‐19128 regulates spermatogenesis by silencing of KIT in chicken
Guo, Q., Xu, L., Bi, Y., Qiu, L., Chen, Y., Kong, L., Pan, R., & Chang, G. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26695 · Cited by 9
An overview of applications of CRISPR-Cas technologies in biomedical engineering
Jamehdor, S., Zaboli, K. A., Naserian, S., Thekkiniath, J., Omidy, H. A., Teimoori, A., Johari, B., Taromchi, A. H., Sasano, Y., & Kaboli, S. (2020) · Folia Histochemica et Cytobiologica · doi:10.5603/fhc.a2020.0023 · Cited by 9
Therapeutic Opportunity in Innate Immune Response Induction by Oncogene-Targeted Drugs
Sisler, D. J., & Heasley, L. E. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0292 · Cited by 9
Han, J., Lim, D., & Yang, K. (2025) · Journal of Tissue Engineering · doi:10.1177/20417314251373039 · Cited by 8
EML4−ALK Variant-Specific Genetic Interactions Shape Lung Tumorigenesis
Diaz-Jimenez, A., Shuldiner, E. G., Somogyi, K., Shih, K. Y., González-Velasco, Ó., Najajreh, M., Kim, S. J., Akkas, F., Murray, C. W., Andrejka, L., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1417 · Cited by 8
Somatic Engineering of Oncogenic Chromosomal Rearrangements: A Perspective
Maddalo, D., & Ventura, A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0726 · Cited by 8
Self-citationRecent advances in host-focused molecular tools for investigating host-gut microbiome interactions
Wang, S., Gong, X., Xiao, F., & Yang, Y. K. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1335036 · Cited by 9
CRISPR Editing in Biological and Biomedical Investigation
Zhang, H., & McCarty, N. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26111 · Cited by 9
Elucidating miRNA Function in Cancer Biology via the Molecular Genetics’ Toolbox
Azlan, A., Rajasegaran, Y., Khor, K. Z., Rosli, A. A., Yik, M. Y., Yusoff, N. M., Heidenreich, O. T., & Moses, E. J. (2022) · Biomedicines · doi:10.3390/biomedicines10040915 · Cited by 8
Recent Advances in Preclinical Developments Using Adenovirus Hybrid Vectors
Ehrke‐Schulz, E., Zhang, W., Gao, J. J., & Ehrhardt, A. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.140 · Cited by 8
Will CRISPR-Cas9 Have Cards to Play Against Cancer? An Update on its Applications
Senthilathiban, D. P., Kuduvalli, S. S., & Anitha, T. S. (2021) · Molecular Biotechnology · doi:10.1007/s12033-020-00289-1 · Cited by 8
Porcine pancreatic ductal epithelial cells transformed with KRASG12D and SV40T are tumorigenic
Bailey, K. L., Cartwright, S., Patel, N. S., Remmers, N. A., Lazenby, A. J., Hollingsworth, M. A., & Carlson, M. A. (2021) · Scientific Reports · doi:10.1038/s41598-021-92852-2 · Cited by 8
Application of CRISPR-Cas9 Technology in Fish
Aich, N., Parhi, J., Mandal, S. C., & Sahoo, L. (2023) · Springer eBooks · doi:10.1007/978-981-99-2981-8_2 · Cited by 7
Li, X., Wang, Z., Man, X., Dai, X., Zhou, Q., & Zhang, S. (2025) · Gynecologic Oncology · doi:10.1016/j.ygyno.2025.02.022 · Cited by 7
Quality control materials for pharmacogenomic testing in the clinic
Lin, G., Zhang, K., Han, Y., & Li, J. (2016) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2016-0755 · Cited by 7
Self-citationA lentivirus-free inducible CRISPR-Cas9 system for efficient targeting of human genes
Bisht, K. K., Grill, S., Graniel, J. V., & Nandakumar, J. (2017) · Analytical Biochemistry · doi:10.1016/j.ab.2017.05.001 · Cited by 7
Zhu, J. J., & Cheng, A. W. (2022) · The CRISPR Journal · doi:10.1089/crispr.2022.0042 · Cited by 7
Singpant, P., Tubsuwan, A., Sakdee, S., Ketterman, A. J., Jearawiriyapaisarn, N., Kurita, R., Nakamura, Y., Songdej, D., Tangprasittipap, A., Bhukhai, K., et al. (2023) · Protein Expression and Purification · doi:10.1016/j.pep.2023.106313 · Cited by 7
Kirchner, M., & Schneider, S. (2015) · Angewandte Chemie · doi:10.1002/ange.201504741 · Cited by 7
From hacking the human genome to editing organs
Tobita, T., Guzman‐Lepe, J., & de l’Hortet, A. C. (2015) · Organogenesis · doi:10.1080/15476278.2015.1120047 · Cited by 7
Borsenberger, V., Croux, C., Daboussi, F., Neuvéglise, C., & Bordes, F. (2020) · ACS Synthetic Biology · doi:10.1021/acssynbio.0c00325 · Cited by 7
Wang, J., Li, X., Zhao, Y., Li, J., Zhou, Q., & Liu, Z. (2015) · Protein & Cell · doi:10.1007/s13238-015-0169-x · Cited by 7
Rajan, S. S., Li, L., Kweh, M. F., Kunkalla, K., Amin, A. D., Agarwal, N., Vega, F., & Schatz, J. H. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018025247 · Cited by 7
Wang, J., Li, X., Zhao, Y., Li, J., Zhou, Q., & Liu, Z. (2015) · Protein & Cell · doi:10.1007/s13238-015-0215-8 · Cited by 7
Murphy, K. C., & Ruscetti, M. A. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041348 · Cited by 7
Buonaiuto, G., Desideri, F., Setti, A., Palma, A., D’Angelo, A., Storari, G., Santini, T., Laneve, P., Trisciuoglio, D., & Ballarino, M. (2025) · Nature Communications · doi:10.1038/s41467-025-62754-2 · Cited by 7
Efficient and precise inversion of genomic DNA from large to chromosomal scale
Zhang, A., Sun, X., Wu, Y. X., Gao, P., Zhang, R., Zhang, M., Xie, S., Fan, W., Zhang, Y., & Yin, H. (2025) · Nature Chemical Biology · doi:10.1038/s41589-025-02033-9 · Cited by 6
Hu, Q., Rix, L. L. R., Desai, B., Miroshnychenko, D., Li, X., Welsh, E. A., Fang, B., Wright, G. M., Chaudhary, N., Kroeger, J. L., et al. (2025) · Science Signaling · doi:10.1126/scisignal.ads7662 · Cited by 6
Neuronal feedback loop of the suprachiasmatic nucleus generates robust circadian rhythms
Wang, M., Tsuno, Y., Peng, Y., Islam, M. T., Matsui, A., Maejima, T., & Mieda, M. (2026) · Nature Communications · doi:10.1038/s41467-025-68218-x · Cited by 6
Chang, L., Masada, M., Kojima, M., & Yamamoto, N. (2021) · Journal of Neuroscience · doi:10.1523/jneurosci.1371-21.2021 · Cited by 6
Aich, M., Ansari, A. H., Ding, L., Iešmantavičius, V., Paul, D., Choudhary, C., Maiti, S., Buchholz, F., & Chakraborty, D. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113177 · Cited by 6
In vitro gene editing using primary cells derived from Cas9-expressing pigs
Kim, S., No, J.-G., Lee, S., Choi, A., Hyung, N., Lee, J. Y., Kwak, T., Ju, W. S., Lee, J.-Y., Lee, P., et al. (2024) · Journal of Animal Science and Technology · doi:10.5187/jast.2024.e77 · Cited by 6
Cancer diagnosis and immunotherapy in the age of CRISPR
Cook, P. J., & Ventura, A. (2018) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22702 · Cited by 6
Self-citationKazama, Y., Hirano, T., Abe, T., & Matsunaga, S. (2018) · CYTOLOGIA · doi:10.1508/cytologia.83.125 · Cited by 6
Multiscale profiling of enzyme activity in cancerPreprint
Amini, A. P., Kirkpatrick, J. D., Wang, C. S., Jaeger, A. M., Su, S., Naranjo, S., Zhong, Q., Cabana, C. M., Jacks, T., & Bhatia, S. N. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.11.468288 · Cited by 6
Maddalo, D., Manchado, E., Concepcion, C. P., Bonetti, C., Vidigal, J. A., Han, Y.-C., Ogrodowski, P., Crippa, A., Rekhtman, N., de Stanchina, E., et al. (2015) · Nature · doi:10.1038/nature14571 · Cited by 6
Self-citationDiscrepancies in indel software resolution with somatic CRISPR/Cas9 tumorigenesis models
Brockman, Q. R., Scherer, A., McGivney, G. R., Gutierrez, W. R., Rytlewski, J. D., Sheehan, A. P., Warrier, A., Laverty, E. A., Roughton, G. A., Carnevale, N. C., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-41109-1 · Cited by 5
Rodent models of tumours of the central nervous system
Brandner, S. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13729 · Cited by 5
The CRISP(Y) Future of Pediatric Soft Tissue Sarcomas
Pomella, S., & Rota, R. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00178 · Cited by 5
Yi, H., Yun, Y., Choi, W. H., Hwang, H.-Y., Cha, J. H., Seok, H., Song, J., Lee, J. H., Oh, S. H., Lee, S.-Y., et al. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102199 · Cited by 5
Nonviral CRISPR/Cas9 mutagenesis for streamlined generation of mouse lung cancer models
Lara‐Sáez, I., Mencía, Á., Recuero, E., Li, Y., García, M., Oteo, M., Gallego, M. I., Enguita, A. B., de Prado-Verdún, D., Sigen, A., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2322917121 · Cited by 5
Tanaka, S. (2018) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12059 · Cited by 5
Rapid Generation of Leukemogenic Chromosomal Translocations in Vivo Using CRISPR/Cas9
Huang, Y., Marovca, B., Dettwiler, S., Bode, P. K., Bornhauser, B. C., & Bourquin, J. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000456 · Cited by 5
Human Rights and Legitimate Governance of Existential and Global Catastrophic Risks
Vöeneky, S. (2018) · Cambridge University Press eBooks · doi:10.1017/9781108355704.007 · Cited by 5
Crop Improvement Using Genome Editing
Butler, N., Jiang, J., & Stupar, R. M. (2018) · Plant breeding reviews · doi:10.1002/9781119414735.ch2 · Cited by 5
Naranjo, S., Cabana, C. M., LaFave, L. M., Westcott, P. M. K., Romero, R., Ghosh, A., Liao, L. Z., Schenkel, J. M., Priore, I. S. D., Bhutkar, A. J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.07.471632 · Cited by 5
Preclinical Modeling of Pathway-Targeted Therapy of Human Lung Cancer in the MousePreprint
Vaishnavi, A., Kinsey, C. G., & McMahon, M. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041385 · Cited by 5
Jenkins, K. A., Layton, D., Gough, T. J., O’Neil, T. E., Malaver-Ortega, L. F., Mishra, K., Bruce, K., Morris, K. R., Wise, T. G., Challagulla, A., et al. (2025) · Animal Biotechnology · doi:10.1080/10495398.2025.2523027 · Cited by 4
Prospects and challenges in using engineered lactic acid bacteria in aquaculture applications
Huang, X., Sun, X., Dong, X., Tang, Y., Xu, S., Wu, Y., ShengBiao, H. U., Ren, Y., Tu, Q., & Zhang, Y. (2026) · Engineering Microbiology · doi:10.1016/j.engmic.2026.100275 · Cited by 4
CRISPR in clinical oncology: translational advances from molecular diagnostics to therapeutics
Grigg, S. E., Shembrey, C., Fareh, M., Blombery, P. A., Corn, J. E., Seymour, J. F., & Casan, J. M. L. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01179-2 · Cited by 4
La revolución en ingeniería genética: sistema CRISPR/Cas
da Lammoglia-Cobo, M. F., do Lozano-Reyes, R., el García-Sandoval, C. D., le Avilez-Bahena, C. M., Trejo-Reveles, V., Muñoz-Soto, R. B., & López‐Camacho, C. (2016) · Investigación en Discapacidad · Cited by 4
Alikhanyan, K., Chen, Y., Somogyi, K., Kraut, S., & Sotillo, R. (2021) · Cancers · doi:10.3390/cancers13236027 · Cited by 4
Role ofSTK11inALK‑positive non‑small cell lung cancer (Review)
Zhou, W., Yan, L.-D., Yu, Z.-Q., Li, N., Yang, Y., Wang, M., Chen, Y., Mao, M.-X., Peng, X., & Cai, J. (2022) · Oncology Letters · doi:10.3892/ol.2022.13301 · Cited by 4
CRISPR–Cas9 for Drug Discovery in Oncology
Guichard, S. M. (2017) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2017.08.006 · Cited by 4
The CRISPR Revolution in the Drug Discovery Workflow: An Industry Perspective
Lattanzi, A., & Maddalo, D. (2022) · The CRISPR Journal · doi:10.1089/crispr.2022.0002 · Cited by 4
Self-citationA functional sgRNA-CRISPR screening method for generating murine RET and NTRK1 rearranged oncogenes
Schubert, L., Le, A. T., Hinz, T. K., Navarro, A., Nelson-Taylor, S. K., Nemenoff, R. A., Heasley, L. E., & Doebele, R. C. (2023) · Biology Open · doi:10.1242/bio.059994 · Cited by 4
Kaur, K. K. (2022) · Current Trends in Biomedical Engineering & Biosciences · doi:10.19080/ctbeb.2022.20.556046 · Cited by 4
Genome Editing with Targetable Nucleases
Pelletier, S. W. (2016) · Springer eBooks · doi:10.1007/978-3-319-34148-4_1 · Cited by 4
Nanodelivery of Anticancer Agents in Melanoma
Chen, J., & Zhang, X. D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802926-8.00015-x · Cited by 4
The Transition of Zebrafish Functional Genetics From Random Mutagenesis to Targeted Integration
Khoury, L. Y. E., Campbell, J. M., & Clark, K. J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-804078-2.00017-9 · Cited by 4
The CRISPR System and Cancer Immunotherapy Biomarkers
Balan, V., & Wang, J. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9773-2_14 · Cited by 4
How CRISPR Is Revolutionizing the Generation of New Models for Cancer ResearchPreprint
Rivera, F. J. S., & Dow, L. E. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041384 · Cited by 4
Murine models of lung adenocarcinoma: Valuable tools for preclinical investigation
Shang, W., Lai, C., Luo, S., & Chen, L. (2025) · Gene · doi:10.1016/j.gene.2025.149802 · Cited by 3
Lang, P. A., Holnsteiner, L., Machlah, Y. M., Friedrich-Becker, S.-K., Bergerhausen, M., Schmitz, R., Schiller, M., Brandenburg, T., Zöller, J., Werner, J., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102411 · Cited by 3
Non-viral delivery of genome-editing tools for treatment of genetic disorders
Yang, J., Chen, Y., Chen, X., & Ping, Y. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.02.014 · Cited by 3
Somatic Genome Editing Goes Viral
Zafra, M. P., & Dow, L. E. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.08.004 · Cited by 3
Selvaraj, D., Dawar, R., Kumar, S. P., & Devi, A. (2021) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2021-0062 · Cited by 3
Söllner, J.-H., Sake, H. J., Frenzel, A., Lechler, R., Herrmann, D., Fuchs, W., & Petersen, B. (2022) · PLoS ONE · doi:10.1371/journal.pone.0279123 · Cited by 3
Du, J., Gong, X., Huang, R., Zheng, B., Chen, C., & Zhang, Y. (2025) · Oncology Reports · doi:10.3892/or.2025.8944 · Cited by 5
Interaction with ERp57 is required for progranulin protection against Type 2 Gaucher disease
Liu, Y., Zhao, X., Jian, J., Hasan, S., & Liu, C.-J. (2023) · BioScience Trends · doi:10.5582/bst.2023.01022 · Cited by 3
Mutagenesis and Transgenesis in Zebrafish
Poulain, F. E. (2017) · Springer eBooks · doi:10.1007/978-3-319-33774-6_1 · Cited by 3
Novel Method of Plasmid DNA Delivery to Mouse Bladder Urothelium by Electroporation
Yu, C., Stefanson, O., Liu, Y., & Wang, Z. A. (2018) · Journal of Visualized Experiments · doi:10.3791/57649-v · Cited by 3
Novel Method of Plasmid DNA Delivery to Mouse Bladder Urothelium by Electroporation
Yu, C., Stefanson, O., Liu, Y., & Wang, Z. A. (2018) · Journal of Visualized Experiments · doi:10.3791/57649 · Cited by 3
A Customizable Protocol for String Assembly gRNA Cloning (STAgR)
Breunig, C., Neuner, A. M., Giehrl‐Schwab, J., Wurst, W., Götz, M., & Stricker, S. H. (2018) · Journal of Visualized Experiments · doi:10.3791/58556 · Cited by 3
Remmers, N. A., Cox, J. L., Grunkemeyer, J. A., Aravind, S., Arkfeld, C. K., Hollingsworth, M. A., & Carlson, M. A. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/267112 · Cited by 3
CRISPR Craft: DNA Editing the Reconstructive Ladder
DeCoster, R. C., Vásconez, H. C., & Butterfield, T. A. (2019) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0000000000006051 · Cited by 3
Naranjo, S., Cabana, C. M., LaFave, L. M., Westcott, P. M. K., Romero, R., Ghosh, A., Liao, L. Z., Schenkel, J. M., Priore, I. S. D., & Jacks, T. (2022) · Research Square · doi:10.21203/rs.3.rs-1281542/v1 · Cited by 3
Una alarma nada excepcional: CRISPR/Cas9 y la edición de la línea germinal en seres humanos
Pallitto, N., & Folguera, G. (2020) · Bioethics Update · doi:10.1016/j.bioet.2019.12.002 · Cited by 3
Metadata
- Authors
- Maddalo, D., Manchado, E., Concepcion, C. P., Bonetti, C., Vidigal, J. A., Han, Y.-C., Ogrodowski, P., Crippa, A., Rekhtman, N., de Stanchina, E., Lowe, S. W., & Ventura, A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Azienda Ospedaliera San Gerardo (IT)
- Corresponding author
- Ventura, Andrea
- ORCID
- Venue
- Nature
- Published
- 2014-10-22
- Volume
- 516
- Issue
- 7531
- Pages
- 423-427
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4270925
- OpenAlex
- W1972759536
- Cited by
- 640
- References
- 30
- Citations by year
- 2026: 21 · 2025: 29 · 2024: 43 · 2023: 45 · 2022: 61 · 2021: 53 · 2020: 53 · 2019: 55 · 2018: 68 · 2017: 65 · 2016: 81 · 2015: 63 · 2014: 2
- FWCI
- 28.86
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-06-24)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Memorial Sloan-Kettering Cancer Center
- National Institutes of Health
- National Cancer Institute (P01CA129243, P01CA013106, P30CA008748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- EML4-ALK fusion, chromosomal rearrangements, non-small cell lung cancer, somatic genome editing, tumor suppressor, oncogene cooperation
- MeSH terms
- Crizotinib, Anaplastic Lymphoma Kinase, Animals, Antineoplastic Agents, Cells, Cultured, Disease Models, Animal, Genetic Engineering, Chromosome Inversion, Lung Neoplasms, Pyrazoles, Pyridines, Translocation, Genetic, Receptor Protein-Tyrosine Kinases, NIH 3T3 Cells, Protein Kinase Inhibitors, Mice, Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR-Cas Systems, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
